Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.

MLA

Li, Weiping, et al. “Targeting MYC Activity in Double-Hit Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements with Epigenetic Bromodomain Inhibitors.” Journal of Hematology & Oncology, vol. 12, no. 1, July 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s13045-019-0761-2.

APA

Li, W., Gupta, S. K., Han, W., Kundson, R. A., Nelson, S., Knutson, D., Greipp, P. T., Elsawa, S. F., Sotomayor, E. M., & Gupta, M. (2019). Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. Journal of Hematology & Oncology, 12(1), N.PAG. https://doi.org/10.1186/s13045-019-0761-2

Chicago

Li, Weiping, Shiv K. Gupta, Weiguo Han, Ryan A. Kundson, Sara Nelson, Darlene Knutson, Patricia T. Greipp, Sherine F. Elsawa, Eduardo M. Sotomayor, and Mamta Gupta. 2019. “Targeting MYC Activity in Double-Hit Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements with Epigenetic Bromodomain Inhibitors.” Journal of Hematology & Oncology 12 (1): N.PAG. doi:10.1186/s13045-019-0761-2.